Top Tech Stocks To Own For 2021

Shares of PERNOD RICARD S/ADR (OTCMKTS:PDRDY) have earned an average rating of “Hold” from the six analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company.

A number of research analysts have recently commented on PDRDY shares. Zacks Investment Research lowered PERNOD RICARD S/ADR from a “buy” rating to a “hold” rating in a report on Thursday, April 5th. ValuEngine raised PERNOD RICARD S/ADR from a “hold” rating to a “buy” rating in a research note on Wednesday, April 4th. Finally, Goldman Sachs Group cut PERNOD RICARD S/ADR from a “buy” rating to a “neutral” rating in a research note on Sunday, March 18th.

Top Tech Stocks To Own For 2021: DCT Industrial Trust Inc(DCT)

DCT Industrial Trust Inc. operates as a publicly owned real estate investment trust. The firm provides its services to companies. Through its fund, it engages in the ownership, operation, and development of real estate properties. The firm specializes in the ownership, acquisition, development, and management of institutional capital management program. It invests in the real estate markets of United States and Mexico. The firm is also invests in selected international markets. It primarily invests in commercial real estate properties, including generic distribution warehouses and light industrial properties. The firm was formerly known as Dividend Capital Trust Inc. DCT Industrial Trust was founded in 2002 and is based in Denver, Colorado with additional offices in Atlanta, Georgia and Dallas, Texas.

Advisors’ Opinion:

  • [By Joseph Griffin]

    Shares of DCT Industrial Trust Inc (NYSE:DCT) have been given an average recommendation of “Hold” by the ten ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $62.83.

  • [By Logan Wallace]

    DECENT (CURRENCY:DCT) traded down 20.5% against the U.S. dollar during the 1-day period ending at 23:00 PM ET on September 5th. Over the last seven days, DECENT has traded 14% lower against the U.S. dollar. DECENT has a total market cap of $8.35 million and approximately $216,900.00 worth of DECENT was traded on exchanges in the last day. One DECENT coin can now be purchased for $0.16 or 0.00002516 BTC on major exchanges including Bittrex, Upbit, BCEX and HitBTC.

Top Tech Stocks To Own For 2021: Banco De Chile(BCH)

Banco de Chile, together with its subsidiaries, provides personal and business baking products and services in Chile and the United States. Its personal banking product line comprises checking accounts, time deposits, money market accounts, demand deposits, now accounts, and prime now accounts. The company also offers lines of credit; credit card products, such as Travel Club, Global Pass, net.card, and PaySafe credit cards; and Internet banking services. Its business banking products and services include financial management products, such as checking accounts, foreign currency accounts, money market accounts, and prime now accounts, as well as a line of credit. In addition, the company provides business Visa, MasterCard, and Travel Club credit cards; and foreign trade services, as well as treasury banking services. Further, it offers various services, including securities brokerage, mutual fund management, factoring, insurance brokerage, financial advisory, and securitiz ation. As of December 31, 2009, the company operated a network of 246 retail branches and 154 Banco CrediChile branches, as well as a network of 1,588 automated teller machines and 415 self-consultation terminals. The company was founded in 1893 and is headquartered in Santiago, Chile.

Advisors’ Opinion:

  • [By Joseph Griffin]

    Shares of Banco de Chile (NYSE:BCH) have been given a consensus recommendation of “Sell” by the seven analysts that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a sell recommendation and two have assigned a hold recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $91.00.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Banco de Chile (BCH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Bitcoin Cash (CURRENCY:BCH) traded 3.3% lower against the US dollar during the one day period ending at 23:00 PM E.T. on August 25th. One Bitcoin Cash coin can now be bought for about $520.83 or 0.07863301 BTC on popular exchanges including Mercatox, BTCC, Bit2C and xBTCe. Bitcoin Cash has a market capitalization of $9.02 billion and approximately $268.90 million worth of Bitcoin Cash was traded on exchanges in the last day. Over the last week, Bitcoin Cash has traded down 5.9% against the US dollar.

Top Tech Stocks To Own For 2021: Syndax Pharmaceuticals, Inc. (SNDX)

We are a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with our initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple negative breast cancer, or TNBC. Entinostat is our oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors. The favorable safety profile of entinostat has been demonstrated in clinical trials in more than 900 cancer patients.   Advisors’ Opinion:

  • [By Logan Wallace]

    A number of brokerages have recently issued reports on SNDX. B. Riley began coverage on shares of Syndax Pharmaceuticals in a research report on Tuesday, January 8th. They issued a “buy” rating and a $40.00 price target on the stock. ValuEngine downgraded shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, February 4th. Finally, Zacks Investment Research downgraded shares of Syndax Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, January 9th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $16.25.

    COPYRIGHT VIOLATION WARNING: “Syndax Pharmaceuticals (SNDX) Set to Announce Earnings on Thursday” was first published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at www.tickerreport.com/banking-finance/4188416/syndax-pharmaceuticals-sndx-set-to-announce-earnings-on-thursday.html.

    About Syndax Pharmaceuticals

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Syndax Pharmaceuticals (SNDX)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *